Antipsychotic Reduction Resident Quality Improvement Great Plains Prioritization Tool Organizations Sharing Knowledge. Improving Health Care. Part 1 Quality Innovation Network CENTERS FOR MEDICARE & MEDICAID SERVICES Start Is the Does Was there a Is this an medication the diagnosis Yes recent Continue No No **MDS** No in the chart match at the low or (< 6 month) to Part 2 referenced the Minimum starting failed (other side) diagnosis? Data Set dose? attempt to (See Box 1) (MDS)? reduce this (See Box 2) medication? No Yes Yes Yes Consult Monitor patient. provider to (May consult Is the Talk to the re-evaluate with provider to medication MDS consider gradual given as Coordinator dose reduction or needed? discontinuation if Box 2 low dose) No **Common Low or Starting Dose** Yes Quetiapine (Seroquel) 12.5-25mg Box 1 Olanzapine (Zyprexa) 2.5-5mg **MDS-Referenced Diagnosis** Consult Risperidone (Risperdal) 0.25-0.5mg Consult provider and Schizophrenia Aripiprazole (Abilify) 2-5mg provider and consider Schizoaffective disorder consider discontinuation Ziprasidone (Geodon) 20-40mg dose reduction **Tourette syndrome** or dose reduction **Huntington disease** Consult MDS 3.0 RAI Manual for more

information

This material was prepared by Health Services Advisory Group (HSAG) and modified by the Great Plains Quality Innovation Network, a Quality Innovation Network – Quality Improvement Organization, under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services (HHS). Views expressed in this material do not necessarily reflect the official views or policy of CMS or HHS, and any reference to a specific product or entity herein does not constitute endorsement of that product or entity by CMS or HHS.T12SOW/GPQIN/QIN-2IO-186/0522

Antipsychotic Reduction Resident Prioritization Tool Part 2

